

## Technology Appraisal Committee Meeting Committee D

**Minutes:** Unconfirmed

**Date and Time:** Wednesday 28 June 2017, 10.00am – 17.10

**Venue:** National Institute for Health and Care Excellence  
Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 4BT

<b>Present:</b>	1. Professor Gary McVeigh (Chair)	Present for all notes
	2. Dr Lindsay Smith (Vice Chair)	Present for all notes
	3. Dr Aomesh Bhatt	Present for all notes
	4. Professor David Bowen	Present for all notes
	5. Dr Matthew Bradley	Present for all notes
	6. Dr Ian Davidson	Present for all notes
	7. Professor Simon Dixon	Present for all notes
	8. Mrs Susan Dutton	Present for all notes
	9. Professor Rachel Elliott	Present for all notes
	10. Mrs Gillian Ells	Present for all notes
	11. Professor Paula Ghaneh	Present for all notes
	12. Dr Rebecca Harmston	Present for all notes
	13. Dr Peter Hall	Present for all notes
	14. Dr David Meads	Present for all notes
	15. Mr Malcolm Oswald	Present for all notes
	16. Mr William Turner	Present for all notes

### In attendance:

Mariana Bacelar	Evidence Review Group representative, Peninsula Technology Assessment Group, BMJ-TAG	Present for notes 16 to 24
Dr Charlotte Benson	Clinical expert, Consultant Medical Oncologist, nominated by GIST Support UK	Present for notes 1 to 16
Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Ramesh Bulusu	Clinical expert, Consultant Oncologist, nominated by GIST Support UK	Present for notes 1 to 16
Dianne Dobson	Patient expert, nominated by Pancreatic Cancer UK	Present for notes 28 to 26
James Dunham	Evidence Review Group representative, Peninsula Technology Assessment Group (PenTAG)	Present for notes 1 to 16

Rui Duarte	Evidence Review Group representative, Liverpool Reviews and Implementation Group	Present for notes 28 to 36
Steve Edwards	Evidence Review Group representative, Peninsula Technology Assessment Group, BMJ-TAG	Present for notes 16 to 24
Christian Griffiths	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 16
Tracey Jones-Hughes	Evidence Review Group representative, Peninsula Technology Assessment Group (PenTAG)	Present for notes 1 to 16
Martin Hoyle	Evidence Review Group representative, Peninsula Technology Assessment Group (PenTAG)	Present for notes 1 to 16
Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Dr John Lear	Clinical expert, Consultant Dermatologist, nominated by Roche	Present for notes 16 to 24
Aimely Lee	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 16 to 27
Dr David Propper	Clinical expert, Consultant and Senior Lecturer in Medical Oncology, nominated by Celgene and NCRI-ACP-RCP-RCR	Present for notes 28 to 36
Dr Sheela Rao	Clinical expert, Consultant Medical Oncologist, nominated by Celgene	Present for notes 28 to 36
Vicky Rockingham	Patient expert, nominated by GIST Support UK	Present for notes 1 to 16
Abitha Senthinathan	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 16
Alex Sexton	Administrator, National Institute for Health and Care Excellence	Present for notes 1 to 16
Raisa Sidhu	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 16 to 27

Angela Stainthorpe	Evidence Review Group representative, Liverpool Reviews and Implementation Group	Present for notes 28 to 36
Emma Tennant	Patient expert, nominated by GIST Support UK	Present for notes 1 to 16
Helen Tucker	Technical Lead, National Institute for Health and Care Excellence	Present for notes 28 to 40
Victoria Wakefield	Evidence Review Group representative, Peninsula Technology Assessment Group, BMJ-TAG	Present for notes 16 to 24
Ian Watson	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 28 to 40
Stephanie Yates	Project Manager, National Institute for Health and Care Excellence	Present for all notes

**Non-public observers:**

Ann Greenwood	Editor, NICE	Present for all notes
Jennifer Sears	Administrator, NICE	Present for notes 1 to 16
Hayley Sharp	Editor, NICE	Present for all notes
Sally Taylor	PIP, NICE	Present for all notes
Jennifer Upton	Apprentice, NICE	Present for notes 1 to 16
Maroulla Whitely	Costings, NICE	Present for all notes

**Notes**

**Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of regorafenib for treating advanced gastrointestinal stromal tumours, vismodegib for treating basal cell carcinoma and paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.
2. Apologies were received from Sumithra Maheswaran, Professor Oluwafemi Oyebode, and Dr Paula Parvulescu.

**Any other Business**

3. None

**Appraisal of regorafenib for treating advanced gastrointestinal stromal tumours**

## Part 1 – Open session

4. The Chair welcomed the invited experts: Dr Charlotte Benson, Dr Ramesh Bulusu James Dunham, Tracey Jones-Hughes, Martin Hoyle, Vicky Rockingham, and Emma Tennant to the meeting and they introduced themselves to the Committee.
5. The Chair welcomed company representatives from Bayer to the meeting.
6. The Chair asked all Committee members to declare any relevant interests
  - 6.1. Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Rebecca Harmston, Dr Peter Hall, Professor Gary McVeigh, Dr David Meads, Mr Malcolm Oswald, Dr Lindsay Smith and Mr William Turner all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for treating advanced gastrointestinal stromal tumours
7. The Chair asked all NICE Staff to declare any relevant interests.
  - 7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for treating advanced gastrointestinal stromal tumours.
8. The Chair asked all other invited guests (/ERG and invited experts, not including observers) to declare their relevant interests.
  - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for treating advanced gastrointestinal stromal tumours.
9. The Chair introduced the lead team, Malcolm Oswald and Professor Simon Dixon, who gave presentations on the clinical effectiveness and cost effectiveness of regorafenib for treating advanced gastrointestinal stromal tumours.
10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## Part 2 – Closed session

13. Discussion on confidential information continued. This information was supplied by the company.
14. The Committee continued to discuss the clinical and cost effectiveness of regorafenib for treating advanced gastrointestinal stromal tumours.
15. The Committee agreed to defer a decision until further economic analysis has been undertaken.

## **Appraisal of vismodegib for treating basal cell carcinoma**

### **Part 1 – Open session**

16. The Vice Chair welcomed the invited experts: Mariana Bacelar, Dr Steve Edwards, Dr John Lear and Dr Victoria Wakefield to the meeting and they introduced themselves to the Committee.
17. The Vice Chair welcomed company representatives from Roche Products to the meeting.
18. The Vice Chair asked all Committee members to declare any relevant interests
  - 18.1. Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Rebecca Harmston, Professor Gary McVeigh, Dr David Meads, Mr Malcolm Oswald, Dr Lindsay Smith and Mr William Turner all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of vismodegib for treating basal cell carcinoma.
  - 18.2. Dr Peter Hall declared a non-personal non-specific financial interest as his university had received funding from the company for his participation in an advisory board.
    - 18.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.
19. The Vice Chair asked all NICE Staff to declare any relevant interests.
  - 19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of vismodegib for treating basal cell carcinoma.
20. The Vice Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of vismodegib for treating basal cell carcinoma.

21. The Vice Chair introduced the lead team, Dr Matthew Bradley, Dr Peter Hall and Dr Rebecca Harmston, who gave presentations on the clinical effectiveness and cost effectiveness of vismodegib for treating basal cell carcinoma.
22. The Vice Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
23. The Vice Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
24. The Vice Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

25. Discussion on confidential information continued. This information was supplied by the company.
26. The Committee continued to discuss the clinical and cost effectiveness of vismodegib for treating basal cell carcinoma.
  - 26.1. The committee decision was based on consensus.
27. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## **Appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer**

### **Part 1 – Open session**

28. The Chair welcomed the invited experts: Dianne Dobson, Rui Duarte, Dr David Proper, Dr Sheela Rao, and Angela Stainthorpe, to the meeting and they introduced themselves to the Committee.
29. The Chair welcomed company representatives from Celgene UK to the meeting.
30. The Chair asked all Committee members to declare any relevant interests
  - 30.1. Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Rebecca Harmston, Professor Gary McVeigh, Dr David Meads, Mr Malcolm Oswald, Dr Lindsay Smith and Mr William Turner all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.
  - 30.2. Dr Peter Hall declared a non-personal non-specific financial interest as his university has received funding from a comparator company for his participation in an advisory board.
    - 30.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

- 30.3. Professor Simon Dixon declared a non-personal non-specific financial interest he is Director of a Health Economics Unit that has undertaken work for a comparator company on unrelated topics; he was not directly involved in the work and his university received payment for the work.  
30.3.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.
31. The Chair asked all NICE Staff to declare any relevant interests.
- 31.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.
32. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
- 32.1. Dianne Dobson, Rui Duarte and Angela Stainthorpe declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.
- 32.2. Dr David Propper declared a personal non-specific financial interest as the company had supplied free of charge a drug for a trial for which he is chief investigator and had reimbursed him for attending an advisory board in 2016.  
32.2.1. It was agreed that this declaration would not prevent Dr David Propper from participating in this section of the meeting
- 32.3. Dr Sheela Rao declared a personal non-specific financial interest as she had attended an advisory board for the company.  
32.3.1. It was agreed that this declaration would not prevent Dr Sheela Rao from participating in this section of the meeting
33. The Chair gave presentations on the clinical effectiveness and cost effectiveness of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.
34. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
35. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
36. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

37. Discussion on confidential information continued. This information was supplied by the company.
38. The Committee continued to discuss the clinical and cost effectiveness of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.

- 38.1. The committee decision was based on consensus.
39. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

40. Wednesday 26 July, 10.00 – 17.00, at Mercure Manchester Piccadilly Hotel